



Br.2

March 15, 2016

Re. License No. 06-28799-01 *103032976*

Licensing Assistance Team
Division of Nuclear Materials Safety
U.S. Nuclear Regulatory Commission, Region I
2100 Renaissance Boulevard, Suite 100
King of Prussia, Pa 19406-2713

Dear Sir or Madam-,

Alexion Pharmaceuticals, Inc. requests the following administrative change to the above reference license:

Effective upon receipt of this letter, Stephen Uden, Senior Vice President Research, has assumed the role of Institutional Official, replacing Daniel Caron. Dr. Uden BSc., MBBS, MRCP is a member of the Research and Development Leadership Team of Alexion Pharmaceuticals and heads all Research functions.

Thank you for your time and assistance in the matter. If you have any questions, or require additional information please do not hesitate to contact Joseph Paradiso, CSP and RSO at paradisoj@alxn.com

Sincerely,

David Hall
Chief Executive Officer

590627
NRC/ONR MATERIALS-002

REC RG 104 07 16 PM 10:44

This is to acknowledge the receipt of your letter application dated

03/15/2016, and to inform you that the initial processing which includes an administrative review has been performed.

☒ 06-28799-01 (Notification)
There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

☐ Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned Mail Control Number 540627
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.

NRC FORM 532 (RI)
(6-96)

Sincerely,
Licensing Assistance Team Leader.